<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04716257</url>
  </required_header>
  <id_info>
    <org_study_id>20201296</org_study_id>
    <nct_id>NCT04716257</nct_id>
  </id_info>
  <brief_title>A Prospective, Multi-center, Real-world Study of Ovarian Metastatic Colorectal Cancer Patients</brief_title>
  <acronym>proOMCRC</acronym>
  <official_title>Impact of Different Treatment Strategies on the Prognosis of Ovarian Metastatic Colorectal Cancer Patients: a Prospective, Multi-center, Real-world Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Hospital of China Medical University, Liaoning Cancer Hospital &amp; Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Changhai Hospital, Naval Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>West China Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective, multi-center, real-world study is conducted to investigate the impact of&#xD;
      different treatment strategies (systemic chemotherapy combined with oophorectomy or with&#xD;
      other local treatment or chemotherapy alone) on the prognosis of ovarian metastatic&#xD;
      colorectal cancer patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study prospectively collects data of patients diagnosed with ovarian metastatic&#xD;
      colorectal cancer, meeting inclusion criteria and signing the informed consent. Patients'&#xD;
      treatment strategies and survival outcome in the real world will be faithfully recorded.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 14, 2021</start_date>
  <completion_date type="Anticipated">January 14, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 14, 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Ovarian specific overall survival</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Calculated from the date of diagnosis with ovarian metastasis to death (caused by cancer) or last follow-up time.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ovarian specific objective response rate</measure>
    <time_frame>6 months</time_frame>
    <description>Response rate of ovarian metastases to systemic chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extra-ovarian specific objective response rate</measure>
    <time_frame>6 months</time_frame>
    <description>Response rate of extra-ovarian metastases to systemic chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>6 months</time_frame>
    <description>Survival time from treatment start to disease progression or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaire</measure>
    <time_frame>6 months</time_frame>
    <description>Quality of life during treatment</description>
  </secondary_outcome>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Ovarian Metastasis</condition>
  <condition>Colorectal Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      samples of ovarian metastases if available&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with ovarian metastatic colorectal cancer.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed colorectal adenocarcinoma;&#xD;
&#xD;
          2. Histologically or radiologically diagnosed with ovarian metastasis, whether or not&#xD;
             combined with metastases in other organs;&#xD;
&#xD;
          3. Women ≥18 years of age;&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group performance status score ≤2;&#xD;
&#xD;
          5. Available imaging data if the disease is measurable according to RECIST criteria&#xD;
             version 1.1; patients are eligible if there is no measurable lesion.&#xD;
&#xD;
          6. Complete medical records;&#xD;
&#xD;
          7. Informed consent form signed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Not ovarian metastatic colorectal cancer confirmed by radiology or histology;&#xD;
&#xD;
          2. Drug abuse or other medical, psychological and social disorders that would interfere&#xD;
             with cooperation with the requirements of the study;&#xD;
&#xD;
          3. Other conditions that would influence patient compliance;&#xD;
&#xD;
          4. Pregnant or breastfeeding female; male and female unwilling to take any contraceptive&#xD;
             measures.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiaofen Li, M.D.</last_name>
    <phone>+86-28-85422589</phone>
    <email>lxf0827@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Cantón</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peirong Ding, Ph.D.</last_name>
      <phone>020-87343533</phone>
      <email>dingpr@sysucc.org.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital of China Medical University, Liaoning Cancer Hospital &amp; Institute</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110042</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rui Zhang, Ph.D.</last_name>
      <phone>024-31916293</phone>
      <email>zhangrui@cancerhosp-ln-cmu.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaofen Li, M.D.</last_name>
      <phone>+86-28-85422589</phone>
      <email>lxf0827@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Changhai Hospital, Naval Medical University</name>
      <address>
        <city>Shanghai</city>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Zhang, Ph.D.</last_name>
      <phone>021-31166666</phone>
      <email>weizhang2000cn@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 15, 2021</study_first_submitted>
  <study_first_submitted_qc>January 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 20, 2021</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>West China Hospital</investigator_affiliation>
    <investigator_full_name>Meng Qiu</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Krukenberg Tumor</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

